91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
This article explores the landscape, regulatory considerations, infrastructural and operational requirements along with future directions for expanding Radiopharmaceuticals and Theranostics therapies into clinical settings.
-
Early intervention in neurodegenerative diseases, such as Alzheimer’s, offers the potential to slow or prevent disease progression, and increase success rates for clinical development.
-
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. Companies must consider price and reimbursement across multiple countries, act early in the development cycle and ensure the evidence required to support their commercial strategy is built into their development plans.
-
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed. Bill Holt outlines how drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.
-
In an 91黑料 survey of 149 biotech professionals, 45% of survey respondents identified protocol design as one the most significant challenges faced when transitioning from preclinical to clinical testing. Here, we discuss considerations for several key elements of protocol development in early phase trials, including selection of healthy volunteers (HVs) or patients, trial design and endpoint selection.
-
Dr. Cyril Clarke at 91黑料 Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
-
Early-phase clinical trials serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market. However, these early stages present significant challenges—nearly half of all drugs entering clinical trials do not make it past phase 1. With the average phase 1 trial costing millions of dollars and consuming valuable time, biotechs have little room for error. This article discusses how partnering with a CRO can benefit a small biotech - helping to fill the gaps in knowledge, resources infrastructure.
-
In this article, Anna Guildford, Senior Consultant, KCR, shares insights on how precision medicine is discussed as a novel approach using genetic and health data to tailor treatments, improving patient outcomes and reducing adverse effects.
-
In this article from BIO-IT World, Dr. Chris Smyth, President of 91黑料 Biotech outlines how despite ongoing challenges, biotech companies can build on growing market confidence by utilising their capital in the most effective and efficient way possible, through improved trial designs, timelines and data-responsive strategies.
-
In this news article, Applied Clinical Trials reports on 91黑料 CEO Steve Cutler’s discussion at the FT US Pharma and Biotech Summit. Topics addressed included the evolution of the CRO and sponsor relationship, the potential of AI in the clinical development space, and how 91黑料 is helping customers build strong portfolios.
